Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia

Journal of Cellular Physiology

Volumn 226, Issue 3, 2011, Pages 822-831

  Evangelisti, Camilla ^a   Ricci, Francesca ^b   Tazzari, Pierluigi ^b   Chiarini, Francesca ^a   Battistelli, Michela ^c   Falcieri, Elisabetta ^c   Ognibene, Andrea ^d   Pagliaro, Pasqualepaolo ^b   Cocco, Lucio ^a   McCubrey, James A ^e   Martelli, Alberto M ^a,f  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF URBINO   (Italy)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e EAST CAROLINA UNIVERSITY   (United States)

^f CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B INHIBITOR; TRICIRIBINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MAMMAL; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; UPREGULATION; WESTERN BLOTTING;

MAMMALIA;

EID: 78650676382     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22407     Document Type: Article

References (43)

1. Berndt N, Yang H, Trinczek B, Betzi S, Zhang Z, Wu B, Lawrence NJ, Pellecchia M, Schönbrunn E, Cheng JQ, Sebti SM. 2010. The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ (in press). DOI: 10.1038/cdd/2010.63.
2. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC. 2009. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235.
3. Brazil DP, Yang ZZ, Hemmings BA. 2004. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29: 233-242.
4. Cabana R, Frolova EG, Kapoor V, Thomas RA, Krishan A, Telford WG. 2006. The minimal instrumentation requirements for Hoechst side population analysis: Stem cell analysis on low-cost flow cytometry platforms. Stem Cells 24: 2573-2581.
5. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. 2008. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
6. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. 2005. The Akt/PKB pathway: Molecular target for cancer drug discovery. Oncogene 24: 7482-7492.
7. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA, Martelli AM. 2008. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 22: 1106-1116.
8. Chiarini F, Fala F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM. 2009. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 69: 3520-3528.
9. Copp J, Manning G, Hunter T. 2009. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): Phospho-Ser 2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69: 1821-1827.
10. Curci R, Battistelli M, Burattini S, D'Emilio A, Ferri P, Lattanzi D, Ciuffoli S, Ambrogini P, Cuppini R, Falcieri E. 2008. Surface and inner cell behaviour along skeletal muscle cell in vitro differentiation. Micron 39: 843-851.
11. Demarest RM, Ratti F, Capobianco AJ. 2008. It's T-ALL about Notch. Oncogene 27: 5082-5091.
12. Engelman JA. 2009. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
13. Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, Khuri FR, Sun SY. 2009. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 69: 8967-8976.
14. Gills JJ, Dennis PA. 2009. Perifosine: Update on a novel Akt inhibitor. Curr Oncol Rep 11: 102-110.
15. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, Hunger SP, Sallan SE, Look AT. 2009. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114: 647-650.
16. Ho MM, Ng AV, Lam S, Hung JY. 2007. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67: 4827-4833.
17. Horn S, Endl E, Fehse B, Weck MM, Mayr GW, Jucker M. 2004. Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3beta signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia 18: 1839-1849.
18. Jotta PY, Ganazza MA, Silva A, Viana MB, da Silva MJ, Zambaldi LJ, Barata JT, Brandalise SR, Yunes JA. 2010. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 24: 239-242.
19. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. 2010. mTOR regulation of autophagy. FEBS Lett 584: 1287-1295.
20. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. 2004. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101: 2788-2801.
21. Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, Cherian C, Devidas M, Linda SB, Taub JW, Matherly LH. 2009. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: A report from the Children's Oncology Group. Leukemia 23: 1417-1425.
22. Levine B, Kroemer G. 2008. Autophagy in the pathogenesis of disease. Cell 132: 27-42.
23. Liu P, Cheng H, Roberts TM, Zhao JJ. 2009. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644.
24. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. 2008. Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist Update 11: 32-50.
25. Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D. 2007. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13: 5883-5888.
26. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA. 2009. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Invest Drugs 18: 1333-1349.
27. Martelli AM, Papa V, Tazzari PL, Ricci F, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Martinelli G, Ottaviani E, Pagliaro P, Horn S, Basecke J, Lindner LH, Eibl H, McCubrey JA. 2010. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia 24: 687-698.
28. Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, Skurk C, Summer R, Fine A, Quesenberry PJ, Walsh K. 2003. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 278: 39068-39075.
29. Moshaver B, van Rhenen A, Kelder A, van der Pol M, Terwijn M, Bachas C, Westra AH, Ossenkoppele GJ, Zweegman S, Schuurhuis GJ. 2008. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 26: 3059-3067.
30. Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD, Burger AM. 2010. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer 102: 815-826.
31. Nyakern M, Cappellini A, Mantovani I, Martelli AM. 2006. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 5: 1559-1570.
32. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM. 2008. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 22: 147-160.
33. Pearce LR, Komander D, Alessi DR. 2010. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 11: 9-22.
34. Pui CH, Robison LL, Look AT. 2008. Acute lymphoblastic leukaemia. Lancet 371: 1030-1043.
35. Ravandi F, Sampath D, Plunkett W, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, Alvarez V, Becker MD, List AF, Sebti S, Kantarjian HM, Lancet J. 2008. Phase I study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancy. Blood 112: 2987 (Abstract).
36. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA, Barata JT. 2008. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118: 3762-3774.
37. Sullivan JP, Minna JD, Shay JW. 2010. Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression and targeted therapy. Cancer Metastasis Rev 29: 61-72.
38. VanderWeele DJ, Zhou R, Rudin CM. 2004. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 3: 1605-1613.
39. Wotring LL, Townsend LB, Jones LM, Borysko KZ, Gildersleeve DL, Parker WB. 1990. Dual mechanisms of inhibition of DNA synthesis by triciribine. Cancer Res 50: 4891-4899.
40. Yamazaki J, Mizukami T, Takizawa K, Kuramitsu M, Momose H, Masumi A, Ami Y, Hasegawa H, Hall WW, Tsujimoto H, Hamaguchi I, Yamaguchi K. 2009. Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma. Blood 114: 2709-2720.
41. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ. 2004. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64: 4394-4399.
42. Yuan TL, Cantley LC. 2008. PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27: 5497-5510.
43. Zhao WL. 2010. Targeted therapy in T-cell malignancies: Dysregulation of the cellular signaling pathways. Leukemia 24: 13-21.